Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Elena Nikulina
Elena Nikulina

Monte Rosa Therapeutics to present Phase 1 MRT-8102 data in CVD risk subjects

Monte Rosa Therapeutics to present Phase 1 MRT-8102 data in CVD risk subjects
Monte Rosa to present trial data

Monte Rosa Therapeutics announced plans to present results from GFORCE-1, its Phase 1 study of MRT-8102 in subjects with elevated cardiovascular disease risk.

The company highlighted its pioneering approach, focusing on the modulation of multiple pathogenic drivers of atherosclerotic cardiovascular disease by MRT-8102. Additional details will be shared in a live webcast.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Is it bad to be rich: Why billionaires are seen as villains
  • By Alena Volkova
  • 2 hours ago
Is it bad to be rich: Why billionaires are seen as villains
Editors' Picks
What is a national blockchain network and does the world need one?
  • By Olena Litvinenko
  • 22 hours ago
What is a national blockchain network and does the world need one?
Editors' Picks
CertiK expert: Hackers are winning the arms race for now
  • By Eugene Komchuk
  • Yesterday
CertiK expert: Hackers are winning the arms race for now
Editors' Picks
All Editors' Top Picks

Latest Monte Rosa News

Monte Rosa Therapeutics launches patient dosing in MRT-2359 combination study for mCRPC
  • By Olga Shendetskaya
  • 24.08.2026
Monte Rosa Therapeutics launches patient dosing in MRT-2359 combination study for mCRPC
Companies
#Monte Rosa
Monte Rosa Therapeutics delivers second quarter financial results and advances pipeline momentum
  • By Ashutosh Sureka
  • 06.08.2026
Monte Rosa Therapeutics delivers second quarter financial results and advances pipeline momentum
Companies
#Monte Rosa
Precision oncology approach for CCNE1-altered cancers advances with new data, Monte Rosa Therapeutics reports
  • By Ashutosh Sureka
  • 22.07.2026
Precision oncology approach for CCNE1-altered cancers advances with new data, Monte Rosa Therapeutics reports
Companies
#Monte Rosa
All Monte Rosa News
  • Alena Volkova
  • 2 hours ago
Is it bad to be rich: Why billionaires are seen as villains
  • Olena Litvinenko
  • 22 hours ago
What is a national blockchain network and does the world need one?
  • Eugene Komchuk
  • Yesterday
CertiK expert: Hackers are winning the arms race for now
  • Dmytro Kharkov
  • Yesterday
Ledger’s spy chip scandal: Can hardware wallets still guard crypto’s cold storage?
  • Pavlo Kot
  • 11.10.2026
Blockchain becomes a burden: Why crypto projects are abandoning L2 networks
  • Hanna Syniavska
  • 12 min ago
CGT reform now faces major short term revenue challenges, Dan Neidle writes
  • Yulia Slavina
  • 22 min ago
Ben Zhou: Next phase of finance focuses on unified trading, investing, payments and wealth management
  • Pavlo Kot
  • 1 hour ago
Solana-linked asset maintains position above support, Sjuul Follings notes
  • Daria Chernytska
  • 1 hour ago
Managing finances while grieving can be difficult, Martin Lewis notes
  • Ksenia Gerey
  • 1 hour ago
Evaluating trading systems using scientific principles, Steve Burns writes
Top News
  • Olga Shendetskaya
  • 2 hours ago
Gold prices rise as Middle East tensions complicate Fed rate outlook
Gold prices rise as Middle East tensions complicate Fed rate outlook
  • Olga Shendetskaya
  • 3 hours ago
Asian tech shares fall sharply as doubts grow over AI profits
Asian tech shares fall sharply as doubts grow over AI profits
  • Eugene Komchuk
  • 3 hours ago
Bitcoin falls below $82,000 before recovering
Bitcoin falls below $82,000 before recovering
  • Andrey Mastykin
  • 19 hours ago
Oil prices hit near two-week highs as Houthi strikes threaten Gulf shipping
Oil prices hit near two-week highs as Houthi strikes threaten Gulf shipping
  • Hanna Syniavska
  • 22 hours ago
India inflation hits 22-month high as energy costs drive price pressures
India inflation hits 22-month high as energy costs drive price pressures
Live News
  • Ivan Andriyenko
  • Now
Plus500 acquires Hedge Capital Markets to expand U.S. trading business
  • Eugene Komchuk
  • Now
Robbers steal nearly $800,000 from crypto trader in the UK
  • Pavlo Kot
  • Now
Binance to shut down mining pool in November after six years
  • Mykhailo Ihnatenko
  • Now
Ethereum price faces key 50 SMA test after another $822M liquidation wave
  • Ksenia Gerey
  • Now
Bitwise CIO names four crypto assets with long-term growth potential
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers